Renoprotective effects of atorvastatin compared with pravastatin on progression of early diabetic nephropathy

Journal of Diabetes Investigation

Volumn 6, Issue 3, 2015, Pages 346-353

  Takazakura, Akiko ^a   Sakurai, Masaru ^b   Bando, Yukihiro ^c   Misu, Hirofumi ^a   Takeshita, Yumie ^a   Kita, Yuki ^a   Shimizu, Akiko ^d   Hayakawa, Tetsuo ^d   Kato, Ken Ichiro ^a   Kaneko, Shuichi ^a   Takamura, Toshinari ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c FUKUI KEN SAISEIKAI HOSPITAL   (Japan)

^d Toyama City Hospital   (Japan)

Author keywords

Early diabetic nephropathy; Renoprotective effects; Statins

Indexed keywords

ALBUMIN; ANTILIPEMIC AGENT; ATORVASTATIN; CREATININE; CYSTATIN C; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIET THERAPY; DISEASE COURSE; DRUG DOSE TITRATION; DRUG MEGADOSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; JAPAN; KIDNEY FUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PLEIOTROPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84928266578     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12296     Document Type: Article

References (32)

1. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
2. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553.
3. Fioretto P, Dodson PM, Ziegler D, et al. Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol 2010; 6: 19-25.
4. Ota T, Takamura T, Ando H, et al. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 2003; 46: 843-851.
5. Adinortey MB, Gyan BE, Adjimani J, et al. Dyslipidaemia Associated with Type 2 Diabetics with Micro and Macrovascular Complications among Ghanaians. Indian J Clin Biochem 2011; 26: 261-268.
6. Keane WF, Tomassini JE, Neff DR. Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis. J Atheroscler Thromb 2013; 20: 123-133.
7. Afzali B, Haydar AA, Vinen K, et al. Beneficial effect of statins on the kidney: the evidence moves from mouse to man. Nephrol Dial Transplant 2004; 19: 1032-1036.
8. Vaziri ND. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease. J Ren Nutr 2010; 20(5 Suppl): S35-S43.
9. Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006; 17: 2006-2016.
10. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006; 145: 117-124.
11. Kimura S, Inoguchi T, Yokomizo H, et al. Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy. Diabetes Obes Metab 2012; 14: 666-669.
12. Colhoun HM, Betteridge DJ, Durrington PN, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009; 54: 810-819.
13. Abe M, Maruyama N, Okada K, et al. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb 2011; 18: 1018-1028.
14. Japan Diabetes Society. Treatment Guide for Diabetes.Tokyo, Japan, Bunkodo, 2007.
15. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest 2012; 3: 39-40.
16. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
17. Horio M, Imai E, Yasuda Y, et al. GFR estimation using standardized serum cystatin C in Japan. Am J Kidney Dis 2013; 61: 197-203.
18. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-734.
19. Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: The TNT (Treating to New Targets) Study. J Am Coll Cardiol 2008; 51: 1448-1454.
20. de Zeeuw D. Different renal protective effect of atorvastatin and rosuvastatin diabetic and non-diabetic renal patients with proteinuria. Results of the PLANET trials 2010. European Renal Association-European Dialysis and Transplant Association Congress, Munich, 2010.
21. Bianchi S, Bigazzi R, Caiazza A, et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003; 41: 565-570.
22. Abe M, Maruyama N, Y Yoshida, et al. Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease. Endocr J 2011; 58: 663-674.
23. Tonelli M, Moyé L, Sacks FM, et al. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003; 14: 1605-1613.
24. Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005; 112: 171-178.
25. Rutter MK, Prais HR, Charlton-Menys V, et al. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1). Diabet Med 2011; 28: 100-108.
26. Shimizu-Tokiwa A, Kobata M, Io H, et al. Serum cystatin C is a more sensitive marker of glomerular function than serum creatinine. Nephron 2002; 92: 224-226.
27. Newman DJ. Cystatin C. Ann Clin Biochem 2002; 39: 89-104.
28. Pergola PE, Raskin P, Toto RD, et al. BEAM Study Investigators. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011; 365: 327-336.
29. Habeos IG, Ziros PG, Chartoumpekis D, et al. Simvastatin activates Keap1/Nrf2 signaling in rat liver. J Mol Med (Berl) 2008; 86: 1279-1285.
30. Chartoumpekis D, Ziros PG, Psyrogiannis A, et al. Simvastatin lowers reactive oxygen species level by Nrf2 activation via PI3K/Akt pathway. Biochem Biophys Res Commun 2010; 396: 463-466.
31. Makabe S, Takahashi Y, Watanabe H, et al. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway. Atherosclerosis 2010; 213: 377-384.
32. Du Y, Zhang X, Ji H, et al. Probucol and atorvastatin in combination protect rat brains in MCAO model:upregulating Peroxiredoxin2, Foxo3a and Nrf2 expression. Neurosci Lett 2012; 509: 110-115.